Posts Tagged ‘initiation’
Determinants of awareness, initiation and maintenance of physical activity among the over-fifties: a Delphi study
To develop effective interventions to stimulate physical activity (PA), insight into its underlying variables is needed. The aim of this study was to obtain an overview of the most relevant determinants of awareness, initiation and maintenance of PA among the over-fifties by means of a three-round Delphi study. In the first round, 17 key-experts outlined possible relevant determinants into an open-ended electronic questionnaire. In the second round, 118 experts completed a structured electronic questionnaire that was based on the first round results, in which they scored each determinant on its relevance. In the third round, experts were asked to re-rate the relevance of each determinant, after feedback was given about the group median relevance score. After three rounds, the experts agreed on 30 relevant determinants of the three phases of PA. When compared with longitudinal studies, the Delphi study pointed out new concepts, such as several post-motivational and social and environmental determinants as possible relevant determinants, suggesting that this method has the potential to trace new and promising determinants. The results further showed that next to similarities, much dissimilarity in relevant determinants of awareness, initiation and maintenance of PA was found, suggesting that most determinants could be phase specific.
Alkermes Announces Initiation Of Multidose Phase 1 Clinical Study Of ALKS 37 For The Treatment Of Opioid-Induced Constipation
Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC)…
Alkermes Announces Initiation Of Phase 1 Clinical Study Of ALKS 37 For The Treatment Of Opioid-Induced Constipation
Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC).
AcelRx Announces Initiation Of Phase 2 Cancer Breakthrough Pain Program
AcelRx Pharmaceuticals, Inc. announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab(TM) product candidate for cancer breakthrough pain control. The primary objective of this multicenter, randomized, placebo-controlled, crossover study is assessment of safety, tolerability and efficacy of ARX-02 relative to placebo in cancer patients experiencing episodic breakthrough pain.
Interventional Spine Announces The Initiation Of Its U.S. Clinical Study For Percutaneous Treatment Of Degenerative Disc Disease
Interventional Spine, Inc. announced the successful completion of the first U.S. out-patient interventional procedure using its PDS System for the treatment of Degenerative Disc Disease (DDD) in the lumbar spine. This milestone marks the initiation of a clinical study pursuant to an Investigational Device Exemption protocol approved by the U.S. Food and Drug Administration in late November 2008.
Rx Drug Compare
Translator
By N2H